All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proglumide
Therapeutic Area: Infections and Infectious Diseases Product Name: M-001
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
Results did not demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Doxycycline Monohydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
PolyPid's D-PLEX100 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the prevention of post abdominal surgery incisional infections.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Doxycycline Monohydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
CLS-AX was observed to be well tolerated in all animal species evaluated, with no overt signs of toxicity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proglumide
Therapeutic Area: Infections and Infectious Diseases Product Name: M-001
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
The purpose of the study is to assess M-001's ability as a standalone non-adjuvanted vaccine to provide clinical protection from circulating influenza strains as measured by reduction of influenza illness rate and severity, as well as to assess M-001's safety.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Doxycycline Monohydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
SHIELD I is a multicenter, randomized, double blind Phase 3 trial designed to assess the efficacy & safety of D-PLEX100 administered concomitantly with the Standard of Care (SoC) vs SoC-treated control arm, to prevent post- abdominal surgery incisional infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proglumide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The NIAID-supported Phase 2 trial was conducted under an FDA Investigational New Drug application (IND), and NIAID’s Division of Microbiology and Infectious Diseases (DMID) has submitted the final CSR to the FDA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Aurum Ventures
Deal Size: $58.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 05, 2020
Details:
PolyPid's lead candidate D-PLEX100 is currently in a Phase 3 trial for bone surgical site infections (SSIs) and the company is planning to initiate a Phase 3 trial for abdominal SSIs set to begin in the 3Q 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): M-001
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Funding May 20, 2020
Details:
BiondVax's pivotal, Phase 3 trial in Europe is ongoing. The trial, which is assessing M‑001's ability to provide clinical protection from any circulating influenza strain, is being conducted with volunteers aged 50+ (with half aged 65+) over two flu seasons in 7 countries.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Doxycycline Monohydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
SHIELD will evaluate D-PLEX100 plus the standard of care (SoC) versus SoC only for the prevention of sternal wound infection post-cardiac surgery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proglumide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2020
Details:
The data, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
